Emily P. Friar

Emily P. Friar

Auto-generated profile, based on publicly available information

Emily P. Friar

School of Chemistry and Forensic Science, Ingram Building, University of Kent, Canterbury, Kent, CT2 7NH, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
CICinzia Imberti
Cinzia Imberti
FLFrederik Lermyte
Frederik Lermyte
EFEmily P. Friar
Emily P. Friar
POPeter B. O'COnnor
Peter B. O'COnnor
PSPeter J. Sadler
Peter J. Sadler
The novel Pt(IV) complex trans,trans-[Pt(N3)2(Py)2(OH)(OCO-(PEG)2-NHCSNH-Ph-NCS)] (Pt4) conjugates to the side chain of lysine amino acids in proteins under mild conditions. Reaction with myoglobin generated a bioconjugate that was stable in the dark, but released a Pt(IV) prodrug upon visible light irradiation. A similar procedure was used to conjugate Pt4 to the antibody trastuzumab, resulting in the first photoactivatable Pt(IV)-antibody conjugate, demonstrating potential for highly selective cancer phototherapy.

19 April 2023 in Chemico-Biological Interactions
Verified
Journal Article
Open access
BABilal Ahmad
Bilal Ahmad
EFEmily P. Friar
Emily P. Friar
MVMuhammad Sufyan Vohra
Muhammad Sufyan Vohra
NKNasar Khan
Nasar Khan
Christopher SerpellChristopher Serpell
Christopher Serpell
EWENG HWA WONG
ENG HWA WONG
Hydroxylated polymethoxyflavones (HPMFs) have been shown to possess various anti-disease effects, including against obesity. This study investigates the anti-obesity effects of HPMFs in further detail, aiming to gain understanding of their mechanism of action in this context. The current study demonstrates that two HPMFs; 3'-hydroxy-5,7,4',5'-tetramethoxyflavone (3'OH-TetMF) and 4'-hydroxy-5,7,3',5'-tetramethoxyflavone (4'OH-TetMF) possess anti-obesity effects. They both significantly reduced pancreatic lipase activity in a competitive manner as demonstrated by molecular docking and kinetic studies. In cell studies, it was revealed that both of the HPMFs suppress differentiation of 3T3-L1 mouse embryonic fibroblast cells during the early stages of adipogenesis. They also reduced expression of key adipogenic and lipogenic marker genes, namely peroxisome proliferator-activated receptor-gamma (PPARγ), CCAAT/enhancer-binding protein α and β (C/EBP α and β), adipocyte binding protein 2 (aP2), fatty acid synthase (FASN), and sterol regulatory element-binding protein 1 (SREBF 1). They also enhanced the expression of cell cycle genes, i.e., cyclin D1 (CCND1) and C-Myc, and reduced cyclin A2 expression. When further investigated, it was also observed that these HPMFs accelerate lipid breakdown (lipolysis) and enhance lipolytic genes expression. Moreover, they also reduced the secretion of proteins (adipokines), including pro-inflammatory cytokines, from mature adipocytes. Taken together, this study concludes that these HPMFs have anti-obesity effects, which are worthy of further investigation.